Articles & Video
Back to business? Demand for trials returning, says Icon
Icon says demand is recovering with bookings for its own services as well as those of soon-to-be acquired PRA continuing to climb in the second quarter.
Medidata launches tech to tackle patient engagement issues
Medidata aims to increase engagement and awareness for patients before and after clinical trials with the launch of myMedidata Registries.
Trial productivity flat in 2020 but efficiency efforts show promise, IQVIA
Clinical development productivity climbed only slightly in 2020 according to IQVIA’s Institute for human data science, which says longer trials and biopharma’s focus on more complex are the key dynamics.
PE interest in CRO and services sector growing, says report
COVID-19 has increased demand for clinical trials and related services, creating opportunities for private equity (PE) investors, according to new analysis.
Survey highlights lack of minority leadership in life science space
The lack of ethnic minorities and women in leadership roles is the biggest problem with diversity and inclusion in the life sciences space, according to a survey from Informa Connect.
Labcorp builds in oncology with combined trials and testing service
Labcorp has launched an “oncology platform” that combines drug development services and diagnostic testing.
Medpace says careful project selection is key
Medpace says taking on the right clinical projects, working with a range of technologies and across a broad range of therapeutic areas is core to its strategy.
Trial payment firm Greenphire to be acquired by PE
Private equity (PE) firm Thoma Bravo will take over global clinical trial financial software firm Greenphire from The Riverside Company.
Eurofins to help expand COVID-19 testing in US schools and beyond
The US Government has asked Eurofins Scientific’s contract analysis arm to further expand COVID-19 testing in schools, underserved populations, and homeless shelters.
PE firm Keensight taking major stake in Dutch CRO Symeres
Keensight Capital says the high annual growth rate in the drug discovery CRO space helped drive the acquisition of a major stake in Symeres.
Castor: Demand for decentralized trial tech growing due to pandemic
COVID-19 has increased demand for decentralized clinical trials according to Castor, which says its technology is being used to support more than 250 studies targeting the disease and the SARS-CoV-2 virus in 40 countries.
PPD setting up biomarker and bioanalysis lab in Suzhou, China
PPD says new multipurpose lab in Suzhou will help local drug developers and international firms targeting the Chinese market.
Altasciences: Calvert buy raises status in mid-sized CRO space
Altasciences says the acquisition of preclinical CRO Calvert Laboratories will strengthen its position as a one-stop solution for outsourced early-phase drug development.
Home-based digital trial tech firm Curebase secures $15m
Curebase has secured $15 million to advance its “home-based” digital trials platform, which it claims can reach “any patient, anywhere.”
Clinipace and dMed cite China as a key global trial market
Local presence and regulatory knowledge is vital when testing drugs in China say soon-to-be merged CROs Clinipace and dMed.
Survey: Decentralized trials to take center stage post-COVID
Decentralized trials will grow in popularity, according to research which suggests firms that adopted the approach as a result of COVID-19 are likely to continue using it after the pandemic is over.
N-SIDE launches app to optimize clinical manufacturing supply chain
The Production App has already saved one biopharma firm €10.5 ($12.8) million by optimizing manufacturing planning through the uncertainty of the clinical process, says N-SIDE.
Imperial hires UK CRO to make COVID-19 challenge virus and run clinical trials
Imperial College scientists have hired UK CRO hVIVO to manufacture a test virus they will use to check if vaccines and antivirals work against new COVID-19 strains.
Charles River furthering manufacturing ambition with Vigene buy
Charles River Labs plans to buy gene-therapy focused CDMO Vigene Biosciences for $300 million, further expanding its presence in the manufacturing space.